Le MyPhuong T, Lanaspa Miguel A, Cicerchi Christina M, Rana Jatinder, Scholten Jeffrey D, Hunter Brandi L, Rivard Christopher J, Randolph R Keith, Johnson Richard J
Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America.
Amway Research and Development, Ada, Michigan, United States of America.
PLoS One. 2016 Jun 20;11(6):e0157458. doi: 10.1371/journal.pone.0157458. eCollection 2016.
In developed countries with westernized diets, the excessive consumption of added sugar in beverages and highly refined and processed foods is associated with increased risk for obesity, diabetes, and cardiovascular diseases. As a major constituent of added sugars, fructose has been shown to cause a variety of adverse metabolic effects, such as impaired insulin sensitivity, hypertriglyceridemia, and oxidative stress. Recent studies have shown that ketohexokinase isoform C is the key enzyme responsible in fructose metabolism that drive's fructose's adverse effects. The objective of this study was to identify botanical ingredients with potential for inhibitory activity against ketohexokinase-C and fructose-induced metabolic effects by using a series of in vitro model systems.
Extracts from 406 botanicals and 1200 purified phytochemicals were screened (initial concentration of 50 μg/mL and 50 μM, respectively) for their inhibitory activity using a cell free, recombinant human ketohexokinase-C assay. Dose response evaluations were conducted on botanical extracts and phytochemicals that inhibited ketohexokinase-C by > 30% and > 40%, respectively. Two different extract lots of the top botanical candidates were further evaluated in lysates of HepG2 cells overexpressing ketohexokinase-C for inhibition of fructose-induced ATP depletion. In addition, extracts were evaluated in intact Hep G2 cells for inhibition of fructose-induced elevation of triglyceride and uric acid production.
Among the botanical extracts, phloretin (Malus domestica) extracts were the most potent (IC50: 8.9-9.2 μg/mL) followed by extracts of Angelica archangelica (IC50: 22.6 μg/mL-57.3 μg/mL). Among the purified phytochemicals, methoxy-isobavachalcone (Psoralea corylifolia, IC50 = 0.2 μM) exhibited the highest potency against ketohexokinase isoform C activity followed by osthole (Angelica archangelica, IC50 = 0.7 μM), cratoxyarborenone E (Cratoxylum prunifolium, IC50 = 1.0 μM), and α-/γ-mangostin (Cratoxylum prunifolium, IC50 = 1.5 μM). Extracts of Angelica archangelica, Garcinia mangostana, Petroselinum crispum, and Scutellaria baicalensis exhibited ketohexokinase inhibitory activity and blocked fructose-induced ATP depletion and fructose-induced elevation in triglyerides and uric acid.
Angelica archangelica, Garcinia mangostana, Petroselinum crispum, and Scutellaria baicalensis were the top four botanical candidiates identified with inhibitory activity against ketohexokinase-C. Future studies are needed to show proof of mechanism and the efficacy of these botanical extracts in humans to blunt the negative metabolic effects of fructose-containing added sugars.
在饮食西化的发达国家,饮料及高度精制和加工食品中添加糖的过量摄入与肥胖、糖尿病及心血管疾病风险增加相关。作为添加糖的主要成分,果糖已被证明会引发多种不良代谢效应,如胰岛素敏感性受损、高甘油三酯血症及氧化应激。近期研究表明,酮己糖激酶同工型C是果糖代谢中的关键酶,它导致果糖产生不良影响。本研究的目的是通过一系列体外模型系统,鉴定对酮己糖激酶-C及果糖诱导的代谢效应具有潜在抑制活性的植物成分。
使用无细胞重组人酮己糖激酶-C检测法,对406种植物提取物和1200种纯化植物化学物质进行筛选(初始浓度分别为50μg/mL和50μM),以检测其抑制活性。对分别抑制酮己糖激酶-C超过30%和40%的植物提取物和植物化学物质进行剂量反应评估。对排名靠前的植物候选物的两个不同提取物批次,在过表达酮己糖激酶-C的HepG2细胞裂解物中进一步评估其对果糖诱导的ATP消耗的抑制作用。此外,在完整的HepG2细胞中评估提取物对果糖诱导的甘油三酯升高和尿酸产生的抑制作用。
在植物提取物中,根皮素(苹果)提取物活性最强(IC50:8.9 - 9.2μg/mL),其次是白芷提取物(IC50:22.6μg/mL - 57.3μg/mL)。在纯化植物化学物质中,甲氧基异补骨脂查耳酮(补骨脂,IC50 = 0.2μM)对酮己糖激酶同工型C活性的抑制作用最强,其次是蛇床子素(白芷,IC50 = 0.7μM)、厚壳桂二氢黄酮E(厚壳桂,IC50 = 1.0μM)和α-/γ-山竹黄酮(厚壳桂,IC50 = 1.5μM)。白芷、山竹、皱叶欧芹和黄芩的提取物表现出酮己糖激酶抑制活性,并阻断了果糖诱导的ATP消耗以及果糖诱导的甘油三酯和尿酸升高。
白芷、山竹、皱叶欧芹和黄芩是鉴定出的对酮己糖激酶-C具有抑制活性的前四种植物候选物。未来需要开展研究,以证明这些植物提取物在人体中的作用机制及功效,从而减轻含果糖添加糖的负面代谢影响。